Table 2.

Patient and treatment characteristics

Patient Number	Age	Metastatic regions	Number of regions	Previous therapy (number of regimes)		p53 expr (%)	Total number of vacc	Clinical outcome after six vacc	Induced or increased p53 immune response	Survival after one vacc (months)
				Chemo	Endocrine
Response at one evaluation
14	58	liver	1	0	2	0	10	SD	+	14.5
15	47	nodal	1	0	0	80	9	SD	+	9
17	46	nodal	1	0	2	40	9	SD	NA	26.5
19	64	nodal	1	0	2	30	>10	SD	−	21
21	44	pleura, bone, nodal, ascites	4	0	1	30	10	PR minor	−	12.5
29	58	lung	1	3	0	90	>10	SD	+	13
35	74	lung, liver	2	2	2	nd	10	SD	+	5.5
37	66	nodal, skin	2	5	1	nd	8	PR minor	−	>21
PD at one evaluation
13	72	nodal, skin	2	1	1	0	7	PD	(+)	4
16	54	pleura, liver, bone	3	2	2	0	5	PD	−	2
20	59	skin, lung , bone, nodal	4	3	1	100	6	PD	NA	7.5
22	33	lung, pleura, liver, bone, nodal	5	2	1	0	5	PD	NA	2
23	46	nodal	1	1	0	90	7	PD	−	13
26	51	lung	1	3	1	0	6	PD	−	10
27	64	liver, bone	2	2	2	0	6	PD	−	2
28	64	lung, pleura, liver, bone, nodal, ascites	6	2	1	50	5	PD	−	2
31	52	bone	1	0	2	10	7	PD	−	3
36	64	skin	1	1	2	0	6	PD	−	>21
38	62	pleura, liver, bone, nodal	4	1	2	0	6	PD	(+)	9
Early termination
10	51	lung, bone, nodal	3	0	2	0	3	PD	−	<1
11	61	nodal	1	2	1	80	3	PD	ND	<1
12	56	lung, liver, nodal	3	1	1	100	4	PD	+	8
18	36	liver, bone	2	2	2	0	4	PD	+	4.5
30	44	skin, lung, pleura, liver	4	2	3	0	4	PD	−	4
32	58	skin	1	0	2	0	3	PD	−	4
33	56	liver,bone, nodal	3	1	0	0	4	PD	−	1.5

+ Only immune response to a single peptide (see Table 4)